Helix BioPharma Corp. (HBP) - Total Liabilities
Based on the latest financial reports, Helix BioPharma Corp. (HBP) has total liabilities worth CA$3.16 Million CAD (≈ $2.29 Million USD) as of January 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Helix BioPharma Corp. (HBP) investment intensity to see how much of total assets are deployed in long-term investments.
Helix BioPharma Corp. - Total Liabilities Trend (2007–2025)
This chart illustrates how Helix BioPharma Corp.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see HBP total assets.
Helix BioPharma Corp. Competitors by Total Liabilities
The table below lists competitors of Helix BioPharma Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tacheng Real Estate Co Ltd
TWO:6171
|
Taiwan | NT$1.79 Billion |
|
Oil Terminal C
RO:OIL
|
Romania | RON319.26 Million |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
Korea | ₩76.26 Billion |
|
European Residential Real Estate Investment Trust
TO:ERE-UN
|
Canada | CA$515.33 Million |
|
FatPipe, Inc. Common Stock
NASDAQ:FATN
|
USA | $8.96 Million |
|
BIMobject AB
ST:BIM
|
Sweden | Skr110.19 Million |
|
Knafaim
TA:KNFM
|
Israel | ILA187.22 Million |
|
Swift Haulage Bhd
KLSE:5303
|
Malaysia | RM998.63 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Helix BioPharma Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Helix BioPharma Corp. (HBP) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Helix BioPharma Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Helix BioPharma Corp. (2007–2025)
The table below shows the annual total liabilities of Helix BioPharma Corp. from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-07-31 | CA$3.22 Million ≈ $2.33 Million |
+103.67% |
| 2024-07-31 | CA$1.58 Million ≈ $1.14 Million |
-15.70% |
| 2023-07-31 | CA$1.87 Million ≈ $1.35 Million |
-45.09% |
| 2022-07-31 | CA$3.41 Million ≈ $2.47 Million |
-37.50% |
| 2021-07-31 | CA$5.46 Million ≈ $3.95 Million |
+183.53% |
| 2020-07-31 | CA$1.93 Million ≈ $1.39 Million |
-54.39% |
| 2019-07-31 | CA$4.22 Million ≈ $3.05 Million |
+57.85% |
| 2018-07-31 | CA$2.67 Million ≈ $1.93 Million |
+21.32% |
| 2017-07-31 | CA$2.20 Million ≈ $1.59 Million |
+69.02% |
| 2016-07-31 | CA$1.30 Million ≈ $943.29K |
+34.57% |
| 2015-07-31 | CA$969.00K ≈ $700.96K |
-7.01% |
| 2014-07-31 | CA$1.04 Million ≈ $753.77K |
+9.92% |
| 2013-07-31 | CA$948.00K ≈ $685.77K |
-31.90% |
| 2012-07-31 | CA$1.39 Million ≈ $1.01 Million |
-38.35% |
| 2011-07-31 | CA$2.26 Million ≈ $1.63 Million |
-4.04% |
| 2010-07-31 | CA$2.35 Million ≈ $1.70 Million |
+4.30% |
| 2009-07-31 | CA$2.26 Million ≈ $1.63 Million |
+97.20% |
| 2008-07-31 | CA$1.14 Million ≈ $827.55K |
-25.67% |
| 2007-07-31 | CA$1.54 Million ≈ $1.11 Million |
-- |
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical tria… Read more